[go: up one dir, main page]

WO2023215344A3 - Compositions and methods for treating cluster-tic syndrome - Google Patents

Compositions and methods for treating cluster-tic syndrome Download PDF

Info

Publication number
WO2023215344A3
WO2023215344A3 PCT/US2023/020771 US2023020771W WO2023215344A3 WO 2023215344 A3 WO2023215344 A3 WO 2023215344A3 US 2023020771 W US2023020771 W US 2023020771W WO 2023215344 A3 WO2023215344 A3 WO 2023215344A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
tic syndrome
psilocybin
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/020771
Other languages
French (fr)
Other versions
WO2023215344A2 (en
Inventor
Mark Wingertzahn
Jeffrey Jewell
Daniel CARCILLO
Stacey ABBY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wesana Health Inc
Original Assignee
Wesana Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wesana Health Inc filed Critical Wesana Health Inc
Publication of WO2023215344A2 publication Critical patent/WO2023215344A2/en
Publication of WO2023215344A3 publication Critical patent/WO2023215344A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin. The present disclosure also features methods for treating or preventing cluster-tic syndrome, or symptoms thereof, with a cannabidiol and/or psilocybin. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment cluster-tic syndrome, or comorbidities thereof (e.g., depression).
PCT/US2023/020771 2022-05-03 2023-05-03 Compositions and methods for treating cluster-tic syndrome Ceased WO2023215344A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263337971P 2022-05-03 2022-05-03
US63/337,971 2022-05-03

Publications (2)

Publication Number Publication Date
WO2023215344A2 WO2023215344A2 (en) 2023-11-09
WO2023215344A3 true WO2023215344A3 (en) 2023-12-14

Family

ID=88646973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/020771 Ceased WO2023215344A2 (en) 2022-05-03 2023-05-03 Compositions and methods for treating cluster-tic syndrome

Country Status (1)

Country Link
WO (1) WO2023215344A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190350949A1 (en) * 2017-01-18 2019-11-21 Procare Beheer B.V. Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes
WO2020212952A1 (en) * 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2022115798A2 (en) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating migraine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190350949A1 (en) * 2017-01-18 2019-11-21 Procare Beheer B.V. Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes
WO2020212952A1 (en) * 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US20220088041A1 (en) * 2019-04-17 2022-03-24 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2022115798A2 (en) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating migraine

Also Published As

Publication number Publication date
WO2023215344A2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
WO2022115798A3 (en) Compositions and methods for treating migraine
BR112018007982A2 (en) composition, enzymatic reaction and method for preparing a graft copolymer
NO934271L (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
WO2020247701A3 (en) Inhibitors of sarm1
NZ565782A (en) Combination of reduced isoalpha acid isohumulones and an acacia extract for the treatment of metabolic syndrome / syndrome X
WO2005076924A3 (en) Agents for sequestering serum aging factors and uses therefore
BRPI0508644A (en) solid acid catalyst and method of using the same
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
BR9508325A (en) Process for amodification of (co) polymers and use of an organic peroxide composition
EP4501327A3 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton s tyrosinekinase (btk) degraders
WO2021146320A8 (en) Antibody molecules to c5ar1 and uses thereof
BR112021023845A2 (en) Dithiocarbamate fungicide macromolecular complexes
WO2023215344A3 (en) Compositions and methods for treating cluster-tic syndrome
BRPI0408827A (en) preserved ophthalmic compositions
BR9908427A (en) Pharmaceutical compositions and use thereof
BR112022006016A2 (en) METHODS AND MATERIALS TO TREAT NEUROTOXICITY
WO2002050163A3 (en) Reduced byproduct high solids polyamine-epihalohydrin compositions
ATE307498T1 (en) ANTIMICROBIAL COMPOSITION
AU2024280384A1 (en) Chemical compounds and uses thereof
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof
YU89103A (en) Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
MY147371A (en) Composition containing oligosaccharides for the treatment / prevention of infections
WO2023287573A3 (en) Anti-c1s antibodies and uses thereof
TW200603785A (en) Compositions containing reduced coenzyme Q10 and carotenoid
WO2022115709A3 (en) Methods and composition for treating metabolic syndrome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23799962

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23799962

Country of ref document: EP

Kind code of ref document: A2